Advertisement
Singapore markets open in 5 hours 17 minutes

  • Straits Times Index

    3,144.76
    -38.85 (-1.22%)
     

  • S&P 500

    5,058.53
    -3.29 (-0.07%)
     

  • Dow

    37,841.12
    +106.01 (+0.28%)
     

  • Nasdaq

    15,888.37
    +3.35 (+0.02%)
     

  • Bitcoin USD

    62,823.71
    -583.05 (-0.92%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • FTSE 100

    7,820.36
    -145.17 (-1.82%)
     

  • Gold

    2,408.30
    +25.30 (+1.06%)
     

  • Crude Oil

    85.47
    +0.06 (+0.07%)
     

  • 10-Yr Bond

    4.6590
    +0.0310 (+0.67%)
     

  • Nikkei

    38,471.20
    -761.60 (-1.94%)
     

  • Hang Seng

    16,248.97
    -351.49 (-2.12%)
     

  • FTSE Bursa Malaysia

    1,535.00
    -7.53 (-0.49%)
     

  • Jakarta Composite Index

    7,164.81
    -7,286.88 (-50.42%)
     

  • PSE Index

    6,404.97
    -157.46 (-2.40%)
     

Compared to Estimates, Danaher (DHR) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2-min read

Danaher (DHR) reported $7.17 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 6.8%. EPS of $2.36 for the same period compares to $2.76 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $7.03 billion, representing a surprise of +1.97%. The company delivered an EPS surprise of +4.42%, with the consensus EPS estimate being $2.26.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Danaher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Total Growth - Organic sales (Core): 6% versus -3.1% estimated by four analysts on average.

  • Total sales- Diagnostics: $2.38 billion versus the four-analyst average estimate of $2.26 billion. The reported number represents a year-over-year change of -10.1%.

  • Total sales- Life Sciences: $1.71 billion compared to the $1.70 billion average estimate based on four analysts. The reported number represents a change of -56% year over year.

  • Total sales- Environmental & Applied Solutions: $1.22 billion versus the four-analyst average estimate of $1.42 billion. The reported number represents a year-over-year change of +4.8%.

View all Key Company Metrics for Danaher here>>>

Shares of Danaher have returned +2.6% over the past month versus the Zacks S&P 500 composite's +4.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Danaher Corporation (DHR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research